- In July 2023, Pfizer received FDA approval for Abrysvo, its respiratory syncytial virus (RSV) vaccine. The vaccine is approved for use in older adults and pregnant women, helping protect infants through maternal immunization. This marks a significant advancement in RSV prevention, addressing high-risk groups and reducing severe RSV-related complications in newborns during their early months.
- In November 2022, GSK’s Arexvy became the first RSV vaccine approved by the FDA for adults aged 60 and above. The vaccine aims to reduce the risk of severe lower respiratory tract disease caused by RSV, particularly in older adults who are more vulnerable to serious complications. Arexvy's approval represents a key milestone in adult RSV protection.
